- Home
- Supplements
- N-Acetyl Cysteine (NAC)
- Glutathione Enhancement
N-Acetyl Cysteine (NAC) for Glutathione Enhancement
NAC supplies cysteine, the rate-limiting amino acid for glutathione synthesis, and reliably raises tissue glutathione in depleted states.
Overview
Verdict
Randomised trials measuring glutathione directly, including brain levels by MR spectroscopy, confirm NAC raises it. Those same trials found no improvement in their clinical endpoints, so the biochemical effect is well established while downstream benefit is condition-dependent.
How It Works
Downstream effects
Dosing & Protocol
Doses used in human trials
| Population | Dose | Schedule | Notes |
|---|---|---|---|
| General glutathione support | 600 mg | Once daily | Common supplement dose; modest but real effect on status |
| Higher-dose adult trials | 2,000-2,700 mg daily | Divided twice daily | The regimen that raised brain glutathione over six months |
| Paediatric research use | Up to 60 mg per kg daily | Divided, supervised | Well tolerated over 12 weeks in trial conditions |
| Hospital antidote use | Weight-based intravenous | Emergency protocol | Never self-administered |
Glutathione status changes over weeks, not days. Trials measuring it ran 12 weeks to six months.
Simple protocol
- 1
Decide what you are measuring against
Glutathione is not something you feel. Anchor use to a specific goal rather than a vague sense of improvement.
- 2
Start at 600 mg daily· 4 weeks
Away from food improves absorption; with food reduces nausea.
- 3
Increase to 1,200 mg daily if tolerated
Split morning and evening. Higher research doses of 2,000 mg and above belong under supervision.
- 4
Support the other substrates
Glutathione also needs glycine and adequate selenium for glutathione peroxidase to function.
- 5
Allow 8-12 weeks
Trials measuring glutathione change ran for months, not weeks.
- 6
Stop two weeks before surgery
Because of possible effects on platelet aggregation.
Evidence
Studies linked to this pairing.
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Conus P, Seidman LJ, Fournier M +4 more
Six months of NAC 2.7 g/d increased brain glutathione levels measured by magnetic resonance spectroscopy.
A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder
Wink LK, Adams R, Wang Z +5 more
A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder
- Direct measurement
- Brain glutathione raised by MR spectroscopy after six months at 2.7 g per day
- Second confirmation
- Plasma glutathione-related markers raised at up to 60 mg per kg daily over 12 weeks
- Clinical endpoints
- Neither trial improved its primary symptom outcome
- Tolerability
- Well tolerated across both trials
- Trial durations
- 12 weeks and 6 months
- Main limitation
- Raising glutathione is confirmed; translating that into clinical benefit is condition-specific and often unproven
Safety
A mechanism, not an outcome
Higher glutathione is confirmed by direct measurement, but both trials that measured it still missed their clinical endpoints. Judge any specific health claim on its own evidence rather than on the glutathione result.
Interactions & Conflicts
Interactions and cautions
| Interacts with | Severity | Mechanism | Action |
|---|---|---|---|
| Nitroglycerin and nitrates | moderate | Enhanced vasodilation | Risk of hypotension and severe headache; medical advice needed |
| Anticoagulants and antiplatelet drugs | moderate | Possible additive effect on platelet aggregation | Discuss with a prescriber; stop two weeks before surgery |
| Asthma | moderate | Bronchospasm reported in susceptible individuals | Start low and stop if wheeze worsens |
| Cystinuria | moderate | Increased urinary cysteine load | Avoid unless supervised |
| Oral glutathione supplements | low | Redundant; NAC targets the rate-limiting step more effectively | No need to combine |
| Activated charcoal | low | Adsorbs oral NAC | Separate doses |
References
- Conus P et al. N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophrenia Bulletin (2018)
- Wink LK et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular Autism (2016)
- NIH LiverTox - Acetylcysteine
Frequently Asked Questions
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.